1
|
Bártolo I, Moranguinho I, Gonçalves P, Diniz AR, Borrego P, Martin F, Figueiredo I, Gomes P, Gonçalves F, Alves AJS, Alves N, Caixas U, Pinto IV, Barahona I, Pinho e Melo TMVD, Taveira N. High Instantaneous Inhibitory Potential of Bictegravir and the New Spiro-β-Lactam BSS-730A for HIV-2 Isolates from RAL-Naïve and RAL-Failing Patients. Int J Mol Sci 2022; 23:ijms232214300. [PMID: 36430777 PMCID: PMC9695772 DOI: 10.3390/ijms232214300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2022] [Revised: 11/16/2022] [Accepted: 11/16/2022] [Indexed: 11/19/2022] Open
Abstract
Integrase inhibitors (INIs) are an important class of drugs for treating HIV-2 infection, given the limited number of drugs active against this virus. While the clinical efficacy of raltegravir and dolutegravir is well established, the clinical efficacy of bictegravir for treating HIV-2 infected patients has not been determined. Little information is available regarding the activity of bictegravir against HIV-2 isolates from patients failing raltegravir-based therapy. In this study, we examined the phenotypic and matched genotypic susceptibility of HIV-2 primary isolates from raltegravir-naïve and raltegravir-failing patients to raltegravir, dolutegravir, and bictegravir, and to the new spiro-β-lactam BSS-730A. The instantaneous inhibitory potential (IIP) was calculated to help predict the clinical activity of bictegravir and BSS-730A. Isolates from raltegravir-naïve patients were highly sensitive to all INIs and BSS-730A. Combined integrase mutations E92A and Q148K conferred high-level resistance to raltegravir, and E92Q and T97A conferred resistance to raltegravir and dolutegravir. The antiviral activity of bictegravir and BSS-730A was not affected by these mutations. BSS-730A displayed strong antiviral synergism with raltegravir. Mean IIP values at Cmax were similar for all INIs and were not significantly affected by resistance mutations. IIP values were significantly higher for BSS-730A than for INIs. The high IIP values of bictegravir and BSS-730A for raltegravir-naïve and raltegravir-resistant HIV-2 isolates highlight their potential value for treating HIV-2 infection. Overall, the results are consistent with the high clinical efficacy of raltegravir and dolutegravir for HIV-2 infection and suggest a promising clinical profile for bictegravir and BSS-730A.
Collapse
Affiliation(s)
- Inês Bártolo
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Inês Moranguinho
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Paloma Gonçalves
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, 2829-511 Caparica, Portugal
| | - Ana Rita Diniz
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Pedro Borrego
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
- Centro de Administração e Políticas Públicas (CAPP), Instituto Superior de Ciências Sociais e Políticas (ISCSP), Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Francisco Martin
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Inês Figueiredo
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
| | - Perpétua Gomes
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, 2829-511 Caparica, Portugal
- Laboratório de Biologia Molecular, LMCBM, SPC, Centro Hospitalar Lisboa Ocidental–HEM, 1649-019 Lisboa, Portugal
| | - Fátima Gonçalves
- Laboratório de Biologia Molecular, LMCBM, SPC, Centro Hospitalar Lisboa Ocidental–HEM, 1649-019 Lisboa, Portugal
| | - Américo J. S. Alves
- Department of Chemistry, Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal
| | - Nuno Alves
- Department of Chemistry, Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal
| | - Umbelina Caixas
- Serviço de Medicina 1.4, Hospital de S. José, CHLC, EPE, and Faculdade de Ciências Médicas, FCM-Nova, Centro de Estudos de Doenças Crónicas–CEDOC, 1649-019 Lisboa, Portugal
| | - Inês V. Pinto
- Medicina Interna, Hospital de Cascais Dr. José de Almeida, 2755-009 Alcabideche, Portugal
| | - Isabel Barahona
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, 2829-511 Caparica, Portugal
| | - Teresa M. V. D. Pinho e Melo
- Department of Chemistry, Coimbra Chemistry Centre-Institute of Molecular Sciences (CQC-IMS), University of Coimbra, 3004-535 Coimbra, Portugal
| | - Nuno Taveira
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, 1649-019 Lisboa, Portugal
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Superior de Ciências da Saúde Egas Moniz, 2829-511 Caparica, Portugal
- Correspondence:
| |
Collapse
|
2
|
Alves AJS, Alves NG, Bártolo I, Fontinha D, Caetano S, Prudêncio M, Taveira N, Pinho E Melo TMVD. Unveiling a family of spiro-β-lactams with anti-HIV and antiplasmodial activity via phosphine-catalyzed [3+2] annulation of 6-alkylidene-penicillanates and allenoates. Front Chem 2022; 10:1017250. [PMID: 36277353 PMCID: PMC9585939 DOI: 10.3389/fchem.2022.1017250] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Accepted: 08/31/2022] [Indexed: 01/02/2023] Open
Abstract
The molecular architecture of spirocyclic compounds has been widely explored within the medicinal chemistry field to obtain new compounds with singular three-dimensional pharmacophoric features and improved bioactivity. Herein, the synthesis of 68 new spirocyclopentene-β-lactams is described, resulting from a rational drug design and structural modulation of a highly promising lead compound BSS-730A, previously identified as having dual antimicrobial activity associated with a novel mechanism of action. Among this diverse library of new compounds, 22 were identified as active against HIV-1, with eight displaying an IC50 lower than 50 nM. These eight compounds also showed nanomolar activity against HIV-2, and six of them displayed micromolar antiplasmodial activity against both the hepatic and the blood stages of infection by malaria parasites, in agreement with the lead molecule’s bioactivity profile. The spirocyclopentene-β-lactams screened also showed low cytotoxicity against TZM-bl and Huh7 human cell lines. Overall, a family of new spirocyclopentene penicillanates with potent activity against HIV and/or Plasmodium was identified. The present structure–activity relationship open avenues for further development of spirocyclopentene-β-lactams as multivalent, highly active broad spectrum antimicrobial agents.
Collapse
Affiliation(s)
- Américo J S Alves
- Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, University of Coimbra, Coimbra, Portugal
| | - Nuno G Alves
- Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, University of Coimbra, Coimbra, Portugal
| | - Inês Bártolo
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
| | - Diana Fontinha
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Soraia Caetano
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Miguel Prudêncio
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Nuno Taveira
- Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Lisboa, Portugal
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal
| | - Teresa M V D Pinho E Melo
- Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, University of Coimbra, Coimbra, Portugal
| |
Collapse
|
3
|
Alves AJS, Silvestre JAD, Pinho e Melo TMVD. Synthesis of novel chiral spiro-β-lactams from nitrile oxides and 6-( Z)-(benzoylmethylene)penicillanate: batch, microwave-induced and continuous flow methodologies. RSC Adv 2022; 12:30879-30891. [PMID: 36349033 PMCID: PMC9614636 DOI: 10.1039/d2ra04848e] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2022] [Accepted: 10/16/2022] [Indexed: 11/07/2022] Open
Abstract
The first examples of the diastereoselective 1,3-dipolar cycloaddition reaction of nitrile oxides and 6-alkylidene penicillanates leading to chiral spiroisoxazoline-penicillanates are reported. The synthesis of this new type of penicillanate involved the selective generation of two consecutive stereogenic centers, including a quaternary chiral center. Furthermore, the present work also describes the outcomes of these 1,3-dipolar cycloaddition reactions under three distinct reaction conditions (conventional heating, microwave irradiation and continuous flow). The successful use of the continuous flow technique as well as the proper selection of the reaction media allowed the development of a sustainable route to chiral spiroisoxazoline-penicillanates. The first examples of the diastereoselective 1,3-dipolar cycloaddition reaction of nitrile oxides and 6-alkylidene penicillanates leading to chiral spiroisoxazoline-penicillanates are reported.![]()
Collapse
Affiliation(s)
- Américo J. S. Alves
- University of Coimbra, Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, 3004-535 Coimbra, Portugal
| | - João A. D. Silvestre
- University of Coimbra, Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, 3004-535 Coimbra, Portugal
| | - Teresa M. V. D. Pinho e Melo
- University of Coimbra, Coimbra Chemistry Centre-Institute of Molecular Sciences and Department of Chemistry, 3004-535 Coimbra, Portugal
| |
Collapse
|
4
|
Alves NG, Bártolo I, Alves AJS, Fontinha D, Francisco D, Lopes SMM, Soares MIL, Simões CJV, Prudêncio M, Taveira N, Pinho E Melo TMVD. Synthesis and structure-activity relationships of new chiral spiro-β-lactams highly active against HIV-1 and Plasmodium. Eur J Med Chem 2021; 219:113439. [PMID: 33887681 DOI: 10.1016/j.ejmech.2021.113439] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2021] [Revised: 03/25/2021] [Accepted: 04/02/2021] [Indexed: 12/20/2022]
Abstract
The synthesis and antimicrobial activity of new spiro-β-lactams is reported. The design of the new molecules was based on the structural modulation of two previously identified lead spiro-penicillanates with dual activity against HIV and Plasmodium. The spiro-β-lactams synthesized were assayed for their in vitro activity against HIV-1, providing relevant structure-activity relationship information. Among the tested compounds, two spirocyclopentenyl-β-lactams were identified as having remarkable nanomolar activity against HIV-1. Additionally, the same molecules showed promising antiplasmodial activity, inhibiting both the hepatic and blood stages of Plasmodium infection.
Collapse
Affiliation(s)
- Nuno Guerreiro Alves
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal
| | - Inês Bártolo
- Instituto de Investigação Do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Américo J S Alves
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal
| | - Diana Fontinha
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| | - Denise Francisco
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| | - Susana M M Lopes
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal
| | - Maria I L Soares
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal
| | - Carlos J V Simões
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal; BSIM Therapeutics, Instituto Pedro Nunes, Coimbra, Portugal
| | - Miguel Prudêncio
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1649-028 Lisboa, Portugal
| | - Nuno Taveira
- Instituto de Investigação Do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal; Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz (IUEM), Caparica, Portugal
| | - Teresa M V D Pinho E Melo
- University of Coimbra, Coimbra Chemistry Centre and Department of Chemistry, 3004-535, Coimbra, Portugal.
| |
Collapse
|
5
|
Affiliation(s)
- Nuno G. Alves
- University of Coimbra Coimbra Chemistry Centre and Department of Chemistry 3004-535 Coimbra Portugal
| | - Américo J. S. Alves
- University of Coimbra Coimbra Chemistry Centre and Department of Chemistry 3004-535 Coimbra Portugal
| | - Maria I. L. Soares
- University of Coimbra Coimbra Chemistry Centre and Department of Chemistry 3004-535 Coimbra Portugal
| | | |
Collapse
|
6
|
Bártolo I, Santos BS, Fontinha D, Machado M, Francisco D, Sepodes B, Rocha J, Mota-Filipe H, Pinto R, Figueira ME, Barroso H, Nascimento T, Alves de Matos AP, Alves AJS, Alves NG, Simões CJV, Prudêncio M, Pinho e Melo TMVD, Taveira N. Spiro-β-lactam BSS-730A Displays Potent Activity against HIV and Plasmodium. ACS Infect Dis 2021; 7:421-434. [PMID: 33395253 DOI: 10.1021/acsinfecdis.0c00768] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The high burden of malaria and HIV/AIDS prevents economic and social progress in developing countries. A continuing need exists for development of novel drugs and treatment regimens for both diseases in order to address the tolerability and long-term safety concerns associated with current treatment options and the emergence of drug resistance. We describe new spiro-β-lactam derivatives with potent (nM) activity against HIV and Plasmodium and no activity against bacteria and yeast. The best performing molecule of the series, BSS-730A, inhibited both HIV-1 and HIV-2 replication with an IC50 of 13 ± 9.59 nM and P. berghei hepatic infection with an IC50 of 0.55 ± 0.14 μM with a clear impact on parasite development. BSS-730A was also active against the erythrocytic stages of P. falciparum, with an estimated IC50 of 0.43 ± 0.04 μM. Time-of-addition studies showed that BSS-730A potentially affects all stages of the HIV replicative cycle, suggesting a complex mechanism of action. BSS-730A was active against multidrug-resistant HIV isolates, with a median 2.4-fold higher IC50 relative to control isolates. BSS-730A was equally active against R5 and X4 HIV isolates and displayed strong synergism with the entry inhibitor AMD3100. BSS-730A is a promising candidate for development as a potential therapeutic and/or prophylactic agent against HIV and Plasmodium.
Collapse
Affiliation(s)
- Inês Bártolo
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Bruna S. Santos
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal
| | - Diana Fontinha
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1648-028 Lisboa, Portugal
| | - Marta Machado
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1648-028 Lisboa, Portugal
| | - Denise Francisco
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1648-028 Lisboa, Portugal
| | - Bruno Sepodes
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - João Rocha
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Hélder Mota-Filipe
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Rui Pinto
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Maria E. Figueira
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
| | - Helena Barroso
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, 2829-511 Monte da Caparica, Portugal
| | - Teresa Nascimento
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, 2829-511 Monte da Caparica, Portugal
| | - António P. Alves de Matos
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, 2829-511 Monte da Caparica, Portugal
| | - Américo J. S. Alves
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal
| | - Nuno G. Alves
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal
| | - Carlos J. V. Simões
- Coimbra Chemistry Centre (CQC), Department of Chemistry, University of Coimbra, 3004-535 Coimbra, Portugal
| | - Miguel Prudêncio
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Avenida Professor Egas Moniz, 1648-028 Lisboa, Portugal
| | | | - Nuno Taveira
- Instituto de investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM), Instituto Universitário Egas Moniz, Quinta da Granja, 2829-511 Monte da Caparica, Portugal
| |
Collapse
|
7
|
Abstract
This review gives an insight into the most recent synthetic methodologies towards spiro-γ-lactams, a class of compounds that are present in a wide range of synthetic bioactive and naturally occurring molecules.
Collapse
Affiliation(s)
- Américo J. S. Alves
- University of Coimbra
- Coimbra Chemistry Centre and Department of Chemistry
- 3004-535 Coimbra
- Portugal
| | - Nuno G. Alves
- University of Coimbra
- Coimbra Chemistry Centre and Department of Chemistry
- 3004-535 Coimbra
- Portugal
| | - Maria I. L. Soares
- University of Coimbra
- Coimbra Chemistry Centre and Department of Chemistry
- 3004-535 Coimbra
- Portugal
| | | |
Collapse
|
8
|
Alves AJS, Pinho e Melo TMVD. Synthesis of Novel Chiral Spiroisoxazolidine‐β‐Lactams from 6‐Alkylidenepenicillanates: A 1,3‐Dipolar Cycloaddition Approach. European J Org Chem 2020. [DOI: 10.1002/ejoc.202001085] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Américo J. S. Alves
- Coimbra Chemistry Centre and Department of Chemistry University of Coimbra 3004‐535 Coimbra Portugal
| | | |
Collapse
|
9
|
Alves AJS, Lopes SMM, Henriques MSC, Paixão JA, Pinho e Melo TMVD. Hetero-Diels-Alder and Ring-Opening Reactions of Furans Applied to the Synthesis of Functionalized Heterocycles. European J Org Chem 2017. [DOI: 10.1002/ejoc.201700453] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Américo J. S. Alves
- CQC and Department of Chemistry; University of Coimbra; 3004-535 Coimbra Portugal
| | - Susana M. M. Lopes
- CQC and Department of Chemistry; University of Coimbra; 3004-535 Coimbra Portugal
| | | | - José A. Paixão
- CFisUC, Department of Physics; University of Coimbra; 3004-516 Coimbra Portugal
| | | |
Collapse
|
10
|
Alves AJS, Rocha F, Amaku M, Ferreira F, Telles EO, Grisi Filho JHH, Ferreira Neto JS, Zylbersztajn D, Dias RA. Economic analysis of vaccination to control bovine brucellosis in the States of Sao Paulo and Mato Grosso, Brazil. Prev Vet Med 2014; 118:351-8. [PMID: 25548080 DOI: 10.1016/j.prevetmed.2014.12.010] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 11/17/2014] [Accepted: 12/10/2014] [Indexed: 11/17/2022]
Abstract
Brucellosis is a zoonotic disease that causes important economic losses in Brazil, and the country has therefore established a national program for its control and eradication. Using data generated in the last national brucellosis survey, we conducted an economic analysis in two Brazilian States with different brucellosis status, Mato Grosso (with high prevalence) and Sao Paulo (with low prevalence). The economic analysis was based on the calculation of the additional benefits and costs of controlling bovine brucellosis through the vaccination of heifers aged between 3 and 8 months with S19 vaccine, considering maximal and minimal impacts of the disease. The analysis showed that vaccinating 90% of the replacement heifers aged 3-8 months of age offers the best economic performance in a vaccination program against bovine brucellosis if compared to vaccination rates of 70% and 80%. Moreover, regions with higher prevalences of bovine brucellosis would experience significant economic advantages when implementing a vaccination strategy to control the disease. This economic analysis will allow decision makers to plan more economically effective vaccination programs.
Collapse
Affiliation(s)
- A J S Alves
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - F Rocha
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - M Amaku
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - F Ferreira
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - E O Telles
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - J H H Grisi Filho
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - J S Ferreira Neto
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil
| | - D Zylbersztajn
- Department of Business, School of Economics, Business and Accounting, University of Sao Paulo, Brazil
| | - R A Dias
- Department of Preventive Veterinary Medicine and Animal Health, School of Veterinary Medicine, University of Sao Paulo, Brazil.
| |
Collapse
|